Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved Th1-Type Cytokine Recall Responses in Human Whole Blood

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2020 Dec 16

PMID 33324841

Citations 4

Authors

Babatunde Ayodeji Adeagbo

Akintunde Oluseto Akinlalu

Tony Phan

Jeff Guderian

Gerhardt Boukes

Elize Willenburg

Caryn Fenner

Oluseye Oladotun Bolaji

Christopher B Fox

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) remains a foremost poverty-related disease with a high rate of mortality despite global immunization with Bacille Calmette-Guérin (BCG). Several adjuvanted recombinant proteins are in clinical development for TB to protect against the disease in infants and adults. Nevertheless, simple mixing of adjuvants with antigens may not be optimal for enhancing the immune response due to poor association. Hence, co-delivery of adjuvants with antigens has been advocated for improved immune response. This report, therefore, presents a strategy of using chemical conjugation to co-deliver an adjuvanted recombinant protein TB vaccine (ID93 + GLA-LSQ). Chemical conjugation involving glutaraldehyde (GA) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) was used to associate the antigen (ID93) to the modified liposome (mGLA-LSQ). The physicochemical stability of the formulations was evaluated using high-performance liquid chromatography (HPLC) (adjuvant content), dynamic light scattering (DLS, particle size analysis), and sodium dodecyl sulfate-polyacrylamide gel (SDS) electrophoresis (protein analysis). The bioactivity was assessed by cytokine stimulation using fresh whole blood from 10 healthy donors. The conjugates of ID93 + mGLA_LSQ maintained liposomal and protein integrity with the two protein chemistries. The GLA and QS21 content of the vaccine were also stable for 3 months. However, only the glutaraldehyde conjugates provoked significant secretion of interleukin-2 (210.4 ± 11.45 vs 166.7 ± 9.15; = 0.0059), interferon-gamma (210.5 ± 14.79 vs 144.1 ± 4.997; = 0.0011), and tumor necrosis factor alpha (2075 ± 46.8 vs 1456 ± 144.8; = 0.0082) compared to simple mixing. Conjugation of recombinant protein (ID93) to the liposome (mGLA_LSQ) through chemical conjugation resulted in a stable vaccine formulation, which could facilitate co-delivery of the subunit vaccine to promote a robust immune response.

Citing Articles

Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.

Mohammad Faizal N, Ramli N, Mat Rani N, Shaibie N, Aarti , Poonsawas P Asian J Pharm Sci. 2023; 18(6):100855.

PMID: 38125653 PMC: 10730353. DOI: 10.1016/j.ajps.2023.100855.

[Potential use of liposomes in tuberculosis treatment].

Jacobo-Delgado Y, Navarro-Tovar G, Rivas-Santiago B Rev Med Inst Mex Seguro Soc. 2023; 61(5):661-669.

PMID: 37769138 PMC: 10599776. DOI: 10.5281/zenodo.8316467.

The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.

Barrera-Rosales A, Rodriguez-Sanoja R, Hernandez-Pando R, Moreno-Mendieta S Microorganisms. 2023; 11(8).

PMID: 37630548 PMC: 10459556. DOI: 10.3390/microorganisms11081988.

Formulated Phospholipids as Non-Canonical TLR4 Agonists.

Liang H, Lykins W, Seydoux E, Guderian J, Phan T, Fox C Pharmaceutics. 2022; 14(12).

PMID: 36559051 PMC: 9788208. DOI: 10.3390/pharmaceutics14122557.

References

Cammarata C, Hughes M, Ofner 3rd C . Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin. Mol Pharm. 2015; 12(3):783-93. PMC: 5585870. DOI: 10.1021/mp5006118. View

Moyle P . Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Biotechnol Adv. 2017; 35(3):375-389. DOI: 10.1016/j.biotechadv.2017.03.005. View

Bertholet S, Ireton G, Kahn M, Guderian J, Mohamath R, Stride N . Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008; 181(11):7948-57. PMC: 2586986. DOI: 10.4049/jimmunol.181.11.7948. View

Moyle P, Toth I . Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013; 8(3):360-76. DOI: 10.1002/cmdc.201200487. View

Coler R, Day T, Ellis R, Piazza F, Beckmann A, Vergara J . The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018; 3:34. PMC: 6123489. DOI: 10.1038/s41541-018-0057-5. View

Penn-Nicholson A, Tameris M, Smit E, Day T, Musvosvi M, Jayashankar L . Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med. 2018; 6(4):287-298. DOI: 10.1016/S2213-2600(18)30077-8. View

Moyle P . Progress in vaccine development. Curr Protoc Microbiol. 2015; 36:18.1.1-18.1.26. DOI: 10.1002/9780471729259.mc1801s36. View

Taneichi M, Tanaka Y, Kakiuchi T, Uchida T . Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One. 2011; 5(11):e15091. PMC: 3020143. DOI: 10.1371/journal.pone.0015091. View

Tait D, Hatherill M, Van Der Meeren O, Ginsberg A, van Brakel E, Salaun B . Final Analysis of a Trial of M72/AS01 Vaccine to Prevent Tuberculosis. N Engl J Med. 2019; 381(25):2429-2439. DOI: 10.1056/NEJMoa1909953. View

10.

Ambrosino D, Sood S, Lee M, Chen D, Collard H, Bolon D . IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants. Pediatr Infect Dis J. 1992; 11(10):855-9. DOI: 10.1097/00006454-199210000-00010. View

11.

Bartczak D, Kanaras A . Preparation of peptide-functionalized gold nanoparticles using one pot EDC/sulfo-NHS coupling. Langmuir. 2011; 27(16):10119-23. DOI: 10.1021/la2022177. View

12.

Scaria P, Chen B, Rowe C, Alani N, Muratova O, Barnafo E . Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine. 2020; 38(34):5480-5489. PMC: 11127250. DOI: 10.1016/j.vaccine.2020.06.018. View

13.

Kramer R, Archer M, Orr M, Cauwelaert N, Beebe E, Huang P . Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach. Int J Nanomedicine. 2018; 13:3689-3711. PMC: 6028350. DOI: 10.2147/IJN.S159839. View

14.

Kreutz M, Giquel B, Hu Q, Abuknesha R, Uematsu S, Akira S . Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One. 2012; 7(7):e40208. PMC: 3393736. DOI: 10.1371/journal.pone.0040208. View

15.

Andersen P, Kaufmann S . Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014; 4(6). PMC: 4031959. DOI: 10.1101/cshperspect.a018523. View

16.

Zegers N, Gerritse K, Deen C, Boersma W, Claassen E . An improved conjugation method for controlled covalent coupling of synthetic peptides to proteins using glutaraldehyde in a dialysis method. J Immunol Methods. 1990; 130(2):195-200. DOI: 10.1016/0022-1759(90)90048-z. View

17.

An S, Scaria P, Chen B, Barnafo E, Muratova O, Anderson C . Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever. Vaccine. 2018; 36(21):2978-2984. PMC: 6771267. DOI: 10.1016/j.vaccine.2018.04.035. View

18.

Hakimi J, Azizi A, Ausar S, Todryk S, Rahman N, Brookes R . An adjuvant-modulated vaccine response in human whole blood. Hum Vaccin Immunother. 2017; 13(9):2130-2134. PMC: 5612035. DOI: 10.1080/21645515.2017.1337616. View

19.

Deen C, Claassen E, Gerritse K, Zegers N, Boersma W . A novel carbodiimide coupling method for synthetic peptides. Enhanced anti-peptide antibody responses. J Immunol Methods. 1990; 129(1):119-25. DOI: 10.1016/0022-1759(90)90428-x. View

20.

Orr M, Fox C, Baldwin S, Sivananthan S, Lucas E, Lin S . Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release. 2013; 172(1):190-200. PMC: 3871206. DOI: 10.1016/j.jconrel.2013.07.030. View